Neoadjuvant Anti-PD-1 Predicts Melanoma Outcomes

(MedPage Today) -- One-dose immune response tied to 63% DFS and 93% OS at 2 years
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news